Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Laura M, Gault"'
Autor:
Weining Z. Robieson, Jeffrey F. Waring, Sandeep Dutta, Jordan Dubow, Ujjwal Das, Laura M. Gault, David P. King, Qi Tang, Gerard Marek
Publikováno v:
Journal of Alzheimer's Disease
Background: Previous studies have investigated associations between apolipoprotein E (APOE)-ɛ4 allele status and acetylcholinesterase inhibitor treatment response in patients with Alzheimer’s disease. The ability to draw definitive conclusions reg
Autor:
Erik D. Roberson, Ilana Fogelman, Irene Litvan, Joel B. Braunstein, Helen Hu, David M. Holtzman, Randall J. Bateman, Davis C. Ryman, Nuno Mendonca, Hana Florian, Tim West, Beatrice Rendenbach-Mueller, Sandra L. Goss, Adam L. Boxer, Philip B. Verghese, Deli Wang, Kumar Budur, Laura M. Gault, Diana R. Kerwin, Yvette Bordelon
Publikováno v:
Alzheimer's & Dementia. 13
Autor:
Laura M. Gault, Eric G. Mohler, George M. Haig, Kathy L. Kohlhaas, Thomas J. Hudzik, James J Lynch, Ana M. Basso, William Bracken, Hongyu Xu
Publikováno v:
Pharmacology, biochemistry, and behavior. 158
ABT-126 is a nicotinic acetylcholine receptor (nAChR) agonist that is selective for the α7 subtype of the receptor. nAChRs are thought to play a role in a variety of neurocognitive processes and have been a pharmacologic target for disorders with co
Autor:
Ahmed A. Othman, Robert A. Lenz, Andreas Meier, George M. Haig, Yili Pritchett, Coleen Hall, Laura M. Gault
Publikováno v:
Journal of Alzheimer's Disease. 42:959-971
Background ABT-288, a highly selective histamine-3 receptor antagonist, demonstrated efficacy across several preclinical cognitive domains, and safety in healthy subjects and elderly volunteers. Objective Evaluate the efficacy and safety of ABT-288 i
Autor:
Laura M. Gault, Yili Pritchett, Scott M. Berry, Qi Tang, Robert A. Lenz, Craig W. Ritchie, Weining Z. Robieson, Andreas Meier, Ahmed A. Othman
Publikováno v:
Alzheimer's Research & Therapy
Gault, L M, Lenz, R A, Ritchie, C W, Meier, A, Othman, A A, Tang, Q, Berry, S, Pritchett, Y & Robieson, W Z 2016, ' ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia : randomized double-blind, placebo and active controlled adaptive trial and open-label extension ', Alzheimer's research & therapy, vol. 8, no. 1, pp. 44 . https://doi.org/10.1186/s13195-016-0210-1
Gault, L M, Lenz, R A, Ritchie, C W, Meier, A, Othman, A A, Tang, Q, Berry, S, Pritchett, Y & Robieson, W Z 2016, ' ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia : randomized double-blind, placebo and active controlled adaptive trial and open-label extension ', Alzheimer's research & therapy, vol. 8, no. 1, pp. 44 . https://doi.org/10.1186/s13195-016-0210-1
Background Results from a phase 2a study indicated that treatment with the novel α7 nicotinic acetylcholine receptor agonist ABT-126 25 mg once daily (QD) was associated with a trend for improvement in cognition in subjects with mild-to-moderate Alz
Autor:
Stanley Lipschitz, Yunzhi Lin, Qi Tang, Weining Z. Robieson, Andreas Meier, Serge Gauthier, Hana Florian, Laura M. Gault, Ahmed A. Othman
Publikováno v:
Journal of Alzheimer's disease : JAD. 51(4)
BACKGROUND ABT-126 is a potent, selective α7 nicotinic acetylcholine receptor agonist with putative procognitive effects as a monotherapy in treating Alzheimer's disease (AD). OBJECTIVE This randomized, double-blind, placebo-controlled multicenter s
Autor:
David S. Miller, Marion Wittmann, Eva-Maria Mandelkow, Susanne Ostrowitzki, Michel Goedert, Lisa J. Bain, James Hendrix, Laura M. Gault, Michael Hutton, David M. Holtzman, Ana M. Catafau, Manuela Polydoro, Sean M. Smith, Eckhard Mandelkow, Maria C. Carrillo
Publikováno v:
Alzheimer's and dementia 12(10), 1033-1039 (2016). doi:10.1016/j.jalz.2016.03.018
Alzheimer's Association Research Roundtable Fall 2015-Tau: From research to clinical development. Tau pathology is recognized as the key driver of disease progression in Alzheimer's and other neurodegenerative diseases. Although this makes tau an att
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::234551578d4e54d18251aa5a4c4365d2
Autor:
Mario D. Saltarelli, Michelle A. Collins, Lenard A. Adler, Yili Pritchett, Christopher J. Kratochvil, Laura M. Gault, Weining Z. Robieson, George Apostol, David Feifel, Walid M. Abi-Saab
Publikováno v:
Psychopharmacology. 219:715-725
α4β2 Neuronal nicotinic receptors (NNRs) are implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD). This study examined the efficacy and safety of the α4β2 NNR partial agonist ABT-089 versus placebo in adults with A
Autor:
Yili Pritchett, Ahmed A. Othman, Weining Z. Robieson, Laura M. Gault, Robert A. Lenz, Craig W. Ritchie
Publikováno v:
Gault, L M, Ritchie, C W, Robieson, W Z, Pritchett, Y, Othman, A A & Lenz, R A 2015, ' A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia ', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 1, no. 1, pp. 81-90 . https://doi.org/10.1016/j.trci.2015.06.001
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Introduction The safety and efficacy of the novel α7 nicotinic acetylcholine receptor agonist ABT-126 were investigated in subjects with mild-to-moderate Alzheimer's dementia (AD). Methods Subjects not currently receiving acetylcholinesterase inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84f469cb7f23eebea9e7c8173b2142b0
https://hdl.handle.net/20.500.11820/268079d0-59bc-4813-93c9-24bbbdb3e1c6
https://hdl.handle.net/20.500.11820/268079d0-59bc-4813-93c9-24bbbdb3e1c6
Autor:
Fuki M. Hisama, Matthew W. State, Adife Gulhan Ercan-Sencicek, Carolyn M. Drazinic, Laura M. Gault, Joseph F. Cubells, Mazin B. Qumsiyeh, Norma J. Nowak
Publikováno v:
American Journal of Medical Genetics Part A. :282-289
Array-based copy number analysis has recently emerged as a rapid means of mapping complex and/or subtle chromosomal abnormalities. We have compared two such techniques, using bacterial artificial chromosome (BAC) and single nucleotide polymorphism (S